Septerna, Inc. (NASDAQ:SEPN) Given Consensus Recommendation of "Moderate Buy" by Analysts

Key Points

• Septerna, Inc. (NASDAQ:SEPN) has received a consensus rating of “Moderate Buy” from analysts, with an average price target of $26.75.
• Recent upgrades from various analysts include Wells Fargo raising the target price to $18.00 and HC Wainwright setting it at $26.00, signaling positive sentiment around the stock.
• Despite these upgrades, Septerna reported disappointing quarterly earnings, missing consensus estimates significantly with earnings per share of ($0.56) against expectations of ($0.05).

Shares of Septerna, Inc. (NASDAQ:SEPN - Get Free Report) have earned a consensus rating of "Moderate Buy" from the five research firms that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $26.75.

Several research analysts have recently weighed in on SEPN shares. Wells Fargo & Company lifted their target price on shares of Septerna from $11.00 to $18.00 and gave the stock an "equal weight" rating in a research report on Friday, May 16th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $25.00 price objective on shares of Septerna in a research note on Friday, September 5th. Wall Street Zen raised shares of Septerna from a "sell" rating to a "hold" rating in a research note on Friday, September 5th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $26.00 target price on shares of Septerna in a research report on Thursday, August 21st.

Hedge Funds Weigh In On Septerna

Large investors have recently made changes to their positions in the business. Tower Research Capital LLC TRC purchased a new stake in shares of Septerna in the fourth quarter worth approximately $25,000. BNP Paribas Financial Markets acquired a new position in Septerna in the 4th quarter valued at approximately $52,000. KLP Kapitalforvaltning AS purchased a new stake in Septerna in the 1st quarter worth approximately $49,000. Zimmer Partners LP acquired a new stake in shares of Septerna during the 4th quarter valued at $229,000. Finally, JPMorgan Chase & Co. boosted its stake in shares of Septerna by 15.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 10,101 shares of the company's stock valued at $107,000 after buying an additional 1,315 shares during the period.

Septerna Stock Up 3.7%

Shares of Septerna stock opened at $15.22 on Wednesday. Septerna has a 12-month low of $4.17 and a 12-month high of $28.99. The firm has a market capitalization of $678.51 million and a PE ratio of -1.51. The stock's fifty day moving average is $12.28 and its 200-day moving average is $9.25.

Septerna (NASDAQ:SEPN - Get Free Report) last released its quarterly earnings results on Monday, August 11th. The company reported ($0.56) earnings per share for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.51). The company had revenue of $0.12 million during the quarter, compared to analyst estimates of $22.50 million. Septerna had a negative net margin of 12,053.03% and a negative return on equity of 31.52%. Analysts expect that Septerna will post -7.11 EPS for the current year.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.